LivaNova (NASDAQ:LIVN) Rating Increased to Strong-Buy at StockNews.com

LivaNova (NASDAQ:LIVN) was upgraded by investment analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Friday.

LIVN has been the topic of several other research reports. Robert W. Baird upped their target price on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Mizuho decreased their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 price objective on shares of LivaNova in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $69.17.

LivaNova Price Performance

Shares of LIVN stock opened at $47.68 on Friday. The stock’s fifty day simple moving average is $48.30 and its 200 day simple moving average is $49.56. LivaNova has a one year low of $43.15 and a one year high of $64.47. The firm has a market cap of $2.59 billion, a price-to-earnings ratio of 113.52 and a beta of 1.00. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

Insider Transactions at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the company’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. This represents a 14.25 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.27% of the stock is owned by company insiders.

Institutional Investors Weigh In On LivaNova

Institutional investors and hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. raised its holdings in LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after purchasing an additional 219 shares during the last quarter. Sterling Capital Management LLC grew its position in shares of LivaNova by 800.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock worth $75,000 after buying an additional 1,441 shares during the period. Central Pacific Bank Trust Division raised its stake in shares of LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after buying an additional 720 shares during the last quarter. Captrust Financial Advisors acquired a new position in LivaNova in the third quarter valued at approximately $217,000. Finally, Sanctuary Advisors LLC bought a new position in LivaNova in the third quarter valued at approximately $219,000. Institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.